French drugmaker Servier is deepening its focus on rare oncology by acquiring Day One Biopharmaceuticals in a deal valued at $2.5 billion. The acquisition, announced this week, is poised to significantly bolster Servier's portfolio, particularly with Day One's flagship drug, Ojemda.
The core of this transaction centers on Ojemda, the sole FDA-approved monotherapy for pediatric low-grade glioma, a prevalent brain tumor in children. This acquisition signals Servier's strategic push to expand its reach in rare and pediatric oncology, aiming to capitalize on Day One's established pipeline and scientific expertise.
Servier plans to fund this acquisition using its existing cash reserves and investments. The deal is anticipated to finalize in the second quarter of the year.
Expanding the Oncology Footprint
This move aligns with Servier's stated "2030 ambition" to lead in rare cancer treatments. The company views the combination as a means to accelerate innovation and extend the reach of Day One's science. Olivier Laureau, President of Servier, highlighted the shared commitment to delivering innovative solutions for patients globally.
Read More: Oil Prices Rise to $120 Near Two-Year High Due to Iran Tensions
Day One Biopharmaceuticals, based in Brisbane, California, was founded with a specific mission to address the "dire lack of therapeutic development in pediatric cancer." The company partners with clinicians, families, and scientists to identify and advance targeted cancer treatments.
Strategic Synergies and Future Prospects
Beyond Ojemda, the acquisition grants Servier access to Day One's broader pipeline, which includes early- to late-stage programs for tovorafenib in pediatric low-grade gliomas, as well as assets targeting adenoid cystic carcinoma and other adult and pediatric solid tumors.
This acquisition comes as Servier continues to develop its own IDH-mutant glioma treatment, Voranigo. Servier's recent activities in oncology dealmaking also include licensing agreements and acquisitions from other companies like Black Diamond Therapeutics, BioNova Pharmaceuticals, and Ideaya Biosciences. The company has also entered into a drug discovery pact with AI biotech Insilico Medicine.
Read More: Doctors Use Secret Words for Patient Pain in London Hospitals
"Servier’s successful track record in rare cancers and its commitment to advancing targeted therapies makes it the ideal home for our portfolio as part of Day One’s mission to bring medicines to patients of all ages with life threatening diseases."— Jeremy Bender, Ph.D., Chief Executive Officer of Day One Biopharmaceuticals
The premium offered for Day One's shares – 68% over its closing price on March 5, 2026, and 86% over its one-month volume-weighted average price – suggests a strong market valuation of Day One's assets and the potential of targeted therapies. Analysts may watch for a potential wave of increased M&A activity within the biotech sector, particularly in rare diseases and oncology, following this substantial move.
Background on the Dealmakers
Servier operates under a unique nonprofit governance model through the Fondation Internationale de Recherche Servier. This structure is often cited as a strength, fostering a patient-centric ethos and a commitment to sustained investment in science.
Day One Biopharmaceuticals positions itself as a company driven by the urgent need for pediatric cancer therapeutics. Its partnership model aims to bring vital treatments to patients facing life-threatening diseases. Financial advisory for Day One was provided by Centerview Partners LLC, with legal counsel from Fenwick & West LLP.
Read More: Meghan Markle's As Ever Brand Leaves Netflix Partnership in London